Injective (INJ) Signals Bullish Recovery Amid Key Market Retest
Injective (INJ) is emerging from a year-long downtrend, showing renewed strength as it breaks past critical resistance levels that previously stifled its growth. Following a significant recovery from its lows, the asset is currently navigating a healthy consolidation phase that will determine whether it can sustain its newfound momentum or fall back into a range-bound state.
Breaking the Barrier and On-Chain Growth
The recent price action saw INJ successfully push through the $6.29 resistance level, a hurdle that had repeatedly rejected recovery attempts in the past. This breakout, which carried the price toward the $7.35 mark, was supported by a notable increase in market participation and strengthening network fundamentals. Data indicates that Injective’s Total Value Locked (TVL) rose by nearly 8% to reach $12.81 million, suggesting that capital continues to flow into the ecosystem even as the price undergoes a short-term retracement. This divergence between price cooling and on-chain growth highlights a resilient underlying demand for the asset.
The Critical Test of Support
As short-term holders lock in profits and Bitcoin enters a corrective phase, INJ has pulled back to test the $6.40–$6.59 region. This consolidation is viewed by analysts as a search for equilibrium following a 27% rally, rather than a failure of the bullish trend. The Relative Strength Index (RSI) remains near 69, indicating that buyers still maintain control of the overall momentum. The immediate focus for traders is whether the former resistance at $6.29 can flip into a solid support floor, which would validate the breakout and set the stage for further gains.
Future Projections and Market Scenarios
If buyers successfully defend the $6.40 zone, the market structure remains firmly bullish, potentially opening a path toward price targets of $7.80 and $8.90. Such a move would confirm that the period of accumulation has transitioned into a sustained expansion phase. Conversely, a failure to hold this support could see INJ slip back into the $5.80–$6.00 demand zone, signaling a lack of conviction among breakout buyers. For now, the alignment of rising TVL and positive technical indicators suggests that Injective is well-positioned for continued growth, provided broader market conditions stabilize.
